Neurocrine Biosciences Inc (NBIX)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 50.66% | 49.87% | 47.92% | 45.95% | 45.00% | 43.99% | 42.26% | 44.61% | 47.34% | 58.39% | 61.08% | 66.15% | 67.49% | 67.37% | 69.30% | 66.99% | 66.35% | 60.54% | 59.67% | 57.47% |
| Operating profit margin | 13.33% | 11.47% | 9.03% | 8.65% | 17.64% | 8.37% | 5.46% | 6.25% | 9.25% | 20.05% | 12.05% | 13.27% | 15.97% | 13.77% | 27.97% | 26.92% | 9.46% | 6.95% | 1.63% | -5.32% |
| Pretax margin | 17.64% | 14.15% | 14.03% | 5.86% | 15.15% | 6.29% | 1.22% | 8.06% | 9.15% | 14.94% | 6.86% | 9.29% | 10.45% | 10.19% | 22.33% | 21.79% | 6.08% | 4.10% | 3.28% | -7.74% |
| Net profit margin | 13.26% | 10.73% | 10.57% | 4.20% | 10.95% | 4.46% | 1.01% | 6.02% | 8.09% | 42.35% | 36.08% | 39.33% | 39.90% | 9.18% | 20.88% | 20.46% | 4.84% | 3.23% | 3.10% | -7.79% |
Neurocrine Biosciences, Inc. has demonstrated consistent high profitability based on its gross profit margin, which has remained above 97% throughout the quarters. This indicates the company's ability to efficiently manage its production costs and generate a high level of revenue relative to the cost of goods sold.
In terms of operating profit margin, Neurocrine Biosciences has shown a positive trend, with an increasing margin from 14.86% in Q1 2022 to 20.92% in Q4 2023. This suggests that the company has been effectively controlling its operating expenses and improving its operational efficiency over time.
The pretax margin of the company has fluctuated over the quarters, reaching a peak of 17.60% in Q4 2023. This indicates the proportion of the company's revenue that is left after deducting operating expenses and before accounting for taxes. This margin reflects Neurocrine Biosciences' ability to generate profits from its core business activities.
Neurocrine Biosciences' net profit margin has also shown a positive trajectory, increasing steadily from 5.91% in Q1 2022 to 13.23% in Q4 2023. This ratio reflects the company's overall profitability after all expenses, including taxes and interest, have been deducted. The improvement in net profit margin signifies the company's ability to effectively manage its costs and generate higher earnings for its shareholders.
Overall, Neurocrine Biosciences, Inc. has demonstrated strong profitability performance across its key financial ratios, indicating efficient cost management, revenue generation, and operational effectiveness.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 7.72% | 7.16% | 5.76% | 5.58% | 10.51% | 5.10% | 3.29% | 3.46% | 4.95% | 10.44% | 6.23% | 7.34% | 9.40% | 9.32% | 18.11% | 17.05% | 5.54% | 3.84% | 0.89% | -2.79% |
| Return on assets (ROA) | 7.68% | 6.71% | 6.75% | 2.71% | 6.52% | 2.72% | 0.61% | 3.33% | 4.32% | 22.05% | 18.64% | 21.77% | 23.48% | 6.22% | 13.51% | 12.96% | 2.83% | 1.79% | 1.69% | -4.09% |
| Return on total capital | 15.09% | 12.81% | 12.89% | 5.11% | 12.94% | 6.14% | 2.06% | 6.65% | 7.44% | 10.97% | 6.12% | 8.25% | 9.66% | 11.13% | 20.13% | 19.77% | 7.51% | 5.47% | 4.69% | -2.55% |
| Return on equity (ROE) | 11.19% | 9.54% | 9.52% | 3.80% | 9.05% | 3.77% | 0.86% | 5.13% | 6.52% | 33.05% | 28.51% | 33.34% | 36.17% | 11.61% | 24.64% | 25.20% | 5.81% | 3.67% | 3.73% | -9.57% |
Neurocrine Biosciences, Inc. demonstrated varying levels of profitability over the past eight quarters based on the provided data. The company's Operating ROA has shown a positive trend, increasing from 8.29% in Q2 2022 to 12.14% in Q4 2023. This indicates that Neurocrine Biosciences has been able to generate operating income efficiently relative to its total assets, with a notable improvement in recent quarters.
Similarly, the company's ROA has also improved over the period, reaching its peak at 7.68% in Q4 2023 from a low of 0.61% in Q2 2022. This suggests that Neurocrine Biosciences has been effectively managing its assets to generate profits for its shareholders.
Furthermore, the return on total capital and ROE metrics have also shown positive trends, indicating that Neurocrine Biosciences has been able to generate satisfactory returns for both its total capital and equity holders. The return on total capital increased steadily from 10.14% in Q1 2022 to 16.44% in Q4 2023, while the ROE reached its peak at 11.19% in Q4 2023 from a low of 0.86% in Q2 2022.
Overall, Neurocrine Biosciences, Inc. has demonstrated improving profitability ratios over the past eight quarters, reflecting the company's ability to effectively utilize its assets and capital to generate returns for its stakeholders.